These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25631214)

  • 1. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model.
    Dalley C; Basarir H; Wright JG; Fernando M; Pearson D; Ward SE; Thokula P; Krishnankutty A; Wilson G; Dalton A; Talley P; Barnett D; Hughes D; Porter NR; Reilly JT; Snowden JA
    J Clin Pathol; 2015 Apr; 68(4):292-300. PubMed ID: 25631214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of the updated NICE haematological cancers (NG47) improving outcomes guidelines across Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England: a UK NEQAS LI survey.
    Cartwright A; Snowden JA; Whitehouse H; Scott S; Whitby L
    J Clin Pathol; 2023 Sep; 76(9):618-623. PubMed ID: 35508367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS).
    Snowden JA; O'Connell S; Hawkins J; Dalley C; Jack A; Mannari D; McNamara C; Scott M; Shenton G; Soilleux E; Macbeth F;
    J Clin Pathol; 2017 Jun; 70(6):461-468. PubMed ID: 28389440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of haematopathology laboratories: a possible model for other pathology services.
    Jack AS; Morgan GJ
    J Pathol; 1998 Mar; 184(3):231-3. PubMed ID: 9614372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organisation of neoplastic haematopathology services: a UK perspective.
    Jack A
    Pathology; 2005 Dec; 37(6):479-92. PubMed ID: 16373228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care.
    Ireland R
    Histopathology; 2011 Jan; 58(1):145-54. PubMed ID: 21261689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of integrated haematopathology laboratories: a new approach to the diagnosis of leukaemia and lymphoma.
    Richards SJ; Jack AS
    Clin Lab Haematol; 2003 Dec; 25(6):337-42. PubMed ID: 14641135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Reduced Waiting Time for Head and Neck Cancer Patients due to a Lean Process Redesign.
    Simons PA; Ramaekers B; Hoebers F; Kross KW; Marneffe W; Pijls-Johannesma M; Vandijck D
    Value Health; 2015 Jul; 18(5):587-96. PubMed ID: 26297086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmarking in pathology: development of an activity-based costing model.
    Burnett L; Wilson R; Pfeffer S; Lowry J;
    Pathology; 2012 Dec; 44(7):644-53. PubMed ID: 23149379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating implementation and operational costs of an integrated tiered CD4 service including laboratory and point of care testing in a remote health district in South Africa.
    Cassim N; Coetzee LM; Schnippel K; Glencross DK
    PLoS One; 2014; 9(12):e115420. PubMed ID: 25517412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interest in and limitations of economic assessment applied to the evaluation of medical strategies: examples in oncological hematology].
    Moatti JP
    Therapie; 2001; 56(2):135-8. PubMed ID: 11471364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Workshop - economic governance mechanisms : for Hematology and Oncology].
    Strech D; Deh U; Schmitz S; Gürkan I; Ostermann H; Krause SW
    Oncol Res Treat; 2015; 38 Suppl 1():3-22. PubMed ID: 25676572
    [No Abstract]   [Full Text] [Related]  

  • 14. Using a Time-Driven Activity-Based Costing Model To Determine the Actual Cost of Services Provided by a Transgenic Core.
    Gerwin PM; Norinsky RM; Tolwani RJ
    J Am Assoc Lab Anim Sci; 2018 Mar; 57(2):157-160. PubMed ID: 29555005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NHS: failing to deliver on Beveridge's promise?
    The Lancet Oncology
    Lancet Oncol; 2018 Jan; 19(1):1. PubMed ID: 29304349
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pursuing the triple aim: evaluation of the integrated care system Gesundes Kinzigtal: population health, patient experience and cost-effectiveness].
    Hildebrandt H; Pimperl A; Schulte T; Hermann C; Riedel H; Schubert I; Köster I; Siegel A; Wetzel M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):383-92. PubMed ID: 25652116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a United States-based laboratory as a hematopathology reference center for a developing country: logistics and results.
    Deetz CO; Scott MG; Ladenson JH; Seyoum M; Hassan A; Kreisel FH; Nguyen TT; Frater JL
    Int J Lab Hematol; 2013 Feb; 35(1):77-81. PubMed ID: 22938565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burn service costing using a mixed model methodology.
    Duncan RT; Dunn KW
    Burns; 2020 May; 46(3):520-530. PubMed ID: 32199624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How much does a diabetes out-patient appointment actually cost? An argument for PLICS.
    Grant P
    J Health Organ Manag; 2015; 29(2):154-69. PubMed ID: 25800330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Funding Cancer Quality Improvement: Payer's Perspective.
    Schumacher H
    J Oncol Pract; 2015 May; 11(3):180-1. PubMed ID: 25804984
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.